Cleft palate
ORPHA:2014Clinical groupMultigenic/multifactorial, Not applicableAntenatal, Neonatal
Эпидемиология54
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Prevalence at birth | 1-5 / 10 000 | 53.6 | Europe | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Europe | Class only |
| Prevalence at birth | 1-5 / 10 000 | 19.6 | Austria | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Austria | Class only |
| Prevalence at birth | 1-5 / 10 000 | 40.8 | Belgium | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Belgium | Class only |
| Prevalence at birth | 1-5 / 10 000 | 56.8 | Croatia | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Croatia | Class only |
| Prevalence at birth | >1 / 1000 | 127.6 | Denmark | Value and class |
| Point prevalence | >1 / 1000 | — | Denmark | Class only |
| Prevalence at birth | 1-5 / 10 000 | 25.5 | France | Value and class |
| Point prevalence | 1-5 / 10 000 | — | France | Class only |
| Prevalence at birth | 1-5 / 10 000 | 47.5 | Germany | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Germany | Class only |
| Prevalence at birth | 6-9 / 10 000 | 67.5 | Hungary | Value and class |
| Point prevalence | 6-9 / 10 000 | — | Hungary | Class only |
| Prevalence at birth | 1-5 / 10 000 | 54.2 | Ireland | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Ireland | Class only |
| Prevalence at birth | 1-5 / 10 000 | 39.6 | Italy | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Italy | Class only |
| Prevalence at birth | 6-9 / 10 000 | 74.7 | Malta | Value and class |
| Point prevalence | 6-9 / 10 000 | — | Malta | Class only |
| Prevalence at birth | 1-5 / 10 000 | 11.7 | Netherlands | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Netherlands | Class only |
| Prevalence at birth | 6-9 / 10 000 | 65.4 | Norway | Value and class |
| Point prevalence | 6-9 / 10 000 | — | Norway | Class only |
| Prevalence at birth | 1-5 / 10 000 | 36.5 | Poland | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Poland | Class only |
| Prevalence at birth | 1-5 / 10 000 | 14.2 | Portugal | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Portugal | Class only |
| Prevalence at birth | 1-5 / 10 000 | 30.7 | Spain | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Spain | Class only |
| Prevalence at birth | 1-5 / 10 000 | 25.1 | Switzerland | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Switzerland | Class only |
| Prevalence at birth | 6-9 / 10 000 | 60.2 | United Kingdom | Value and class |
| Point prevalence | 6-9 / 10 000 | — | United Kingdom | Class only |
| Prevalence at birth | 1-5 / 10 000 | 57.2 | Ukraine | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Ukraine | Class only |
| Prevalence at birth | >1 / 1000 | 101.2 | Australia | Value and class |
| Point prevalence | >1 / 1000 | — | Australia | Class only |
| Prevalence at birth | 1-5 / 10 000 | 52 | Chile | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Chile | Class only |
| Prevalence at birth | 1-5 / 10 000 | 27 | Sudan | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Sudan | Class only |
| Prevalence at birth | 1-5 / 10 000 | 26 | Iran, Islamic Republic of | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Iran, Islamic Republic of | Class only |
| Prevalence at birth | 1-5 / 10 000 | 27 | Mexico | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Mexico | Class only |
| Prevalence at birth | 1-9 / 100 000 | 4 | Bolivia | Value and class |
| Point prevalence | 1-9 / 100 000 | — | Bolivia | Class only |
| Prevalence at birth | 6-9 / 10 000 | 68 | Specific population | Value and class |
| Point prevalence | 6-9 / 10 000 | — | Specific population | Class only |
| Prevalence at birth | 1-5 / 10 000 | 40 | Taiwan, Province of China | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Taiwan, Province of China | Class only |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)